Table 3.
Vaccine coverage prevalence of foreign-born and U.S.-born adolescents by region of birth – National Immunization Survey-Teen, 2014, n = 20,738.
| Region of birth | Coverage prevalence (95% CIa) |
||||
|---|---|---|---|---|---|
| Latin Americab | Asia | Europe | United States | ||
| Routinely recommended vaccines | |||||
| Tdap c ≥1 dose | 93.9 (89.7, 98.2) | 86.7 (78.2, 95.2) | 82.1 (66.5, 97.6) | 90.1 (89.3, 91) | |
| MenACWY c ≥1 dose | 85.5 (77.3, 93.7) | 73.6 (61.1, 86.1) | 73.6 (59.8, 87.3) | 80.0 (78.9, 81.1) | |
| ≥1 dose | 79.0* (69.4, 88.6) | 60.2 (42.2, 78.3) | 47.9 (26.9, 69.0) | 59.3 (57.4, 61.2) | |
| HPV c; Females | ≥2 doses | 60.3 (46.4, 74.1) | 45.4 (24.4, 66.5) | 40.0 (20.3, 59.7) | 50.0 (48, 51.9) |
| ≥3 doses | 39.4 (24.7, 54.2) | 26.2 (11.3, 41.1) | 23.6 (8.3, 39) | 39.8 (37.9, 41.7) | |
| ≥1 dose | 53.2 (37.5, 69.0) | 34.7 (18.0, 51.4) | 40.9 (18.2, 63.7) | 41.4 (39.6, 43.3) | |
| HPV c; Males | ≥2 doses | 36.5 (22.4, 50.5) | 31.8 (15.6, 48.0) | 32.5 (10.3, 54.8) | 31.1 (29.3, 32.9) |
| ≥3 doses | 25.1 (13.4, 36.9) | 28.2 (12.4, 43.9) | 22.4 (2.6, 42.2) | 21.3 (19.6, 22.9) | |
| Catch-Up Vaccines | |||||
| MMR c ≥2 doses | 90.5 (85.4, 95.7) | 87.8 (80.7, 94.8) | 77.6 (61.6, 93.6) | 90.8 (90, 91.6) | |
| Hepatitis B ≥3 doses | 87.3 (78.7, 96) | 85.0 (76.3, 93.7) | 76.3 (60.4, 92.2) | 91.6 (90.9, 92.4) | |
| Varicella vaccination among adolescents with no history of disease | |||||
| ≥1 dose | 89.5 (82.6, 96.3) | 76.2* (60.2, 92.2) | 94.8 (89, 100.0) | 94.8 (94.2, 95.4) | |
| ≥2 doses | 79.3 (70.3, 88.2) | 45.7* (28, 63.4) | 85.5 (76.2, 94.8) | 80.4 (79.2, 81.6) | |
a
CI: Confidence interval.
b
The Latin America category includes Mexico, Caribbean, Central America, and South America.
c
Tdap: Tetanus, diphtheria, and acellular pertussis vaccine; MenACWY: quadrivalent meningococcal conjugate. vaccine; HPV: human papillomavirus vaccine; MMR: measles, mumps, and rubella vaccine.
*
Statistically significantly different from the United States category at the α = 0.05 level.